Prognostic significance of cathepsin L expression in pediatric acute myeloid leukemia

References

• Rubnitz J, Raimondi S, Halbert A, et al. Characteristics and outcome of t (8; 21)-positive childhood acute myeloid leukemia: a single institution’s experience. Leukemia. 2002;16:2072.
   PubMed Web of Science ®Google Scholar
• Von Neuhoff C, Reinhardt D, Sander A, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. JCO. 2010;28:2682–2689.
   PubMed Web of Science ®Google Scholar
• Liu Y, He P, Liu F, et al. Prognostic significance of NPM1 mutations in acute myeloid leukemia: a meta-analysis. Mol Clin Oncol. 2014;2:275–281.
   PubMedGoogle Scholar
• Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001;97:89–94.
   PubMed Web of Science ®Google Scholar
• Johnston DL, Alonzo TA, Gerbing RB, et al. Outcome of pediatric patients with acute myeloid leukemia (AML) and− 5/5q − abnormalities from five pediatric AML treatment protocols: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2013;60:2073–2078.
   PubMedGoogle Scholar
• Hasle H, Alonzo TA, Auvrignon A, et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood. 2007;109:4641–4647.
   PubMed Web of Science ®Google Scholar
• de Rooij JD, Zwaan CM, van den Heuvel-Eibrink M. Pediatric AML: from biology to clinical management. J Clin Med. 2015;4:127–149.
   PubMed Web of Science ®Google Scholar
• Chauhan SS, Goldstein LJ, Gottesman MM. Expression of cathepsin L in human tumors. Cancer Res. 1991;51:1478–1481.
   PubMed Web of Science ®Google Scholar
• Svatek RS, Karam J, Karakiewicz PI, et al. Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma. J Urol. 2008;179:478–484.
   PubMed Web of Science ®Google Scholar
• Herszényi L, Farinati F, Cardin R, et al. Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer. 2008;8:194.
   PubMed Web of Science ®Google Scholar
• Sivaparvathi M, Yamamoto M, Nicolson GL, et al. Expression and immunohistochemical localization of cathepsin L during the progression of human gliomas. Clin Exp Metast. 1996;14:27–34.
   PubMed Web of Science ®Google Scholar
• Didier J, Guillaume N, Frade R. Characterization of human cathepsin L promoter and identification of binding sites for NF-Y, Sp1 and Sp3 that are essential for its activity. Biochem J. 2002;361:173–184.
   PubMed Web of Science ®Google Scholar
• Jean D, Rousselet N, Frade R. Expression of cathepsin L in human tumor cells is under the control of distinct regulatory mechanisms. Oncogene. 2006;25:1474.
   PubMed Web of Science ®Google Scholar
• Seth P, Mahajan VS, Chauhan SS. Transcription of human cathepsin L mRNA species hCATL B from a novel alternative promoter in the first intron of its gene. Gene. 2003;321:83–91.
   PubMed Web of Science ®Google Scholar
• Arora S, Chauhan SS. Identification and characterization of a novel human cathepsin L splice variant. Gene. 2002;293:123–131.
   PubMed Web of Science ®Google Scholar
• Gerber A, Wille A, Welte T, et al. Interleukin-6 and transforming growth factor-β1 control expression of cathepsins B and L in human lung epithelial cells. J Interferon Cytokine Res. 2001;21:11–19.
   PubMed Web of Science ®Google Scholar
• Collette J, Ulku AS, Der CJ, et al. Enhanced cathepsin L expression is mediated by different Ras effector pathways in fibroblasts and epithelial cells. Int J Cancer. 2004;112:190–199.
   PubMed Web of Science ®Google Scholar
• Keerthivasan S, Keerthivasan G, Mittal S, et al. Transcriptional upregulation of human cathepsin L by VEGF in glioblastoma cells. Gene. 2007;399:129–136.
   PubMed Web of Science ®Google Scholar
• Turk V, Brzin J, Kotnik M, et al. Human cysteine proteinases and their protein inhibitors stefins, cystatins and kininogens. Biomed Biochim Acta. 1986;45:1375–1384.
   PubMedGoogle Scholar
• Jain M, Bakhshi S, Shukla AA, et al. Cathepsins B and L in peripheral blood mononuclear cells of pediatric acute myeloid leukemia: potential poor prognostic markers. Ann Hematol. 2010;89:1223–1232.
   PubMed Web of Science ®Google Scholar
• Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction. Anal Biochem. 1987;162:156–159.
   PubMed Web of Science ®Google Scholar
• Mir RA, Chauhan SS. Down regulation of a matrix degrading cysteine protease cathepsin L, by acetaldehyde: role of C/EBPα. PLoS One. 2011;6:e20768.
   PubMed Web of Science ®Google Scholar
• Thomssen C, Schmitt M, Goretzki L, et al. Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer. Clin Cancer Res. 1995;1:741–746.
   PubMed Web of Science ®Google Scholar
• Niedergethmann M, Wostbrock B, Sturm JW, et al. Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma. Pancreas. 2004;29:204–211.
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang S, Wang Q, et al. Overexpression of cysteine cathepsin L is a marker of invasion and metastasis in ovarian cancer. Oncol Rep. 2014;31:1334–1342.
   PubMed Web of Science ®Google Scholar
• Xu X, Yuan G, Liu W, et al. Expression of cathepsin L in nasopharyngeal carcinoma and its clinical significance. Exp Oncol. 2009;31:102–105.
   PubMedGoogle Scholar
• Ruan J, Zheng H, Fu W, et al. Increased expression of cathepsin L: a novel independent prognostic marker of worse outcome in hepatocellular carcinoma patients. PLoS One. 2014;9:e112136.
   PubMedGoogle Scholar
• Samaiya M, Bakhshi S, Shukla AA, et al. Epigenetic regulation of cathepsin L expression in chronic myeloid leukaemia. J Cell Mol Med. 2011;15:2189–2199.
   PubMed Web of Science ®Google Scholar
• Sudhan DR, Pampo C, Rice L, et al. Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model. Int J Cancer. 2016;138:2665–2677.
   PubMed Web of Science ®Google Scholar
• Yin M, Soikkeli J, Jahkola T, et al. TGF-β signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells. Am J Pathol. 2012;181:2202–2216.
   PubMed Web of Science ®Google Scholar
• Guinec N, Dalet-Fumeron V, Pagano M. “In vitro” study of basement membrane degradation by the cysteine proteinases, cathepsins B, B-Like and L. Digestion of collagen IV, laminin, fibronectin, and release of gelatinase activities front basement membrane fibronectin. Biol Chem Hoppe Seyler. 1993;374:1135–1146.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang W, Ding Y, et al. Up-regulation of VEGF and its receptor in refractory leukemia cells. Int J Clin Exp Pathol. 2015;8:5282.
   PubMed Web of Science ®Google Scholar
• Padro T, Bieker R, Ruiz S, et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia. 2002;16:1302.
   PubMed Web of Science ®Google Scholar
• Pruneri G, Bertolini F, Soligo D, et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer. 1999;81:1398.
   PubMed Web of Science ®Google Scholar
• Fiedler W, Graeven U, Ergün S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 1997;89:1870–1875.
   PubMed Web of Science ®Google Scholar
• Müller-Esterl W, Fritz H, Kellermann J, et al. Genealogy of mammalian cysteine proteinase inhibitors. Common evolutionary origin of stefins, cystatins and kininogens. FEBS Lett. 1985;191:221–226.
   PubMed Web of Science ®Google Scholar
• Wegiel B, Jiborn T, Abrahamson M, et al. Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways. PLoS One. 2009;4:e7953.
   PubMed Web of Science ®Google Scholar
• Strojan P, Oblak I, Svetic B, et al. Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis. Br J Cancer. 2004;90:1961–1968.
   PubMed Web of Science ®Google Scholar
• Leto G, Incorvaia L, Flandina C, et al. Clinical impact of Cystatin C/Cathepsin L and Follistatin/Activin a systems in breast cancer progression: a preliminary report. Cancer Invest. 2016;34:415–423.
   PubMed Web of Science ®Google Scholar
• Kothapalli R, Bailey RD, Kusmartseva I, et al. Constitutive expression of cytotoxic proteases and down-regulation of protease inhibitors in LGL leukemia. Int J Oncol. 2003;22:39–40.
   Web of Science ®Google Scholar